Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 196,835 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALL Clear all

Conditions: Erectile Dysfunction, Spinal Cord Injuries
Interventions: tadalafil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: homeopathic remedy in 30C potency, Placebo; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Bipolar Disorder
Interventions: Lithium; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more

Conditions: Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity, DVT, Deep Vein Thrombosis Leg, Thrombus in the Peripheral Venous Vasculature, Peripheral Arterial Disease, Acute Limb Ischemia, Lower Extremity Acute Limb Ischemia, LE ALI
Interventions: Liberant Thrombectomy System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Naples, Florida + 3 more

Conditions: Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
Interventions: Eribulin Mesylate, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • Pasadena, California + 12 more

Conditions: Oral Cavity Cancer, Oropharyngeal Cancer, Lymphedema, Fibrosis
Interventions: LEF measures, Technical measure; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Foot Injuries and Disorders
Interventions: Structure Sensor, Caliper; Device
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Advanced Solid Tumours
Interventions: AZD0156, Olaparib, irinotecan, Fluorouracil, Folinic Acid; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Inflammation
Interventions: Adenosine, Sodium Nitroprusside; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cervical Arthrodesis
Interventions: Cervical arthrodesis with rhBMP-2; Procedure
Lead sponsor: Virginia Spine Institute; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Reston, Virginia

Conditions: Analgesia, Obstetrical
Interventions: Tegaderm dressing + catheter support pad, Tegaderm dressing + Steri-strip dressing, Tegaderm dressing only; Device
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: HIV
Interventions: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM), HIV Stigma Scale Questionnaire, HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12), HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12), Needs and Barriers Assessment, Pre-visit Outreach, Qualitative interview - patient participants, Staff education, Staff Month 7 and 15 Survey - Staff Burden and Engagement, Qualitative interview - staff; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more

Conditions: Generalized Myasthenia Gravis (gMG)
Interventions: CABA-201; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 17
States / cities: Orange, California • Sacramento, California • San Francisco, California + 12 more

Conditions: Colorectal Neoplasms
Interventions: Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Irinotecan; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 71
States / cities: Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more

Conditions: SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Interventions: Urine Collection; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan

Conditions: Healthy
Interventions: Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Kidney Transplant, Liver Transplant
Interventions: Letermovir; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Blood Recovery
Interventions: Hand Wrung, ProCell Wrung; Procedure · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myelodysplastic Syndromes
Interventions: Azacitidine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure
Interventions: Motivational Interviewing tailored intervention; Behavioral
Lead sponsor: Ruth Masterson-Creber; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Total Knee Arthroplasty
Interventions: Pregabalin 50mg, Pregabalin 100mg, Pregabalin 150mg, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: PTSD, Alcohol; Use, Problem
Interventions: Seeking Safety + Signs of Safety toolkit, Treatment as usual; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Search by objective public record fields.

Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury

The Homeogenomic Trial

Lithium Therapy: Understanding Mothers, Metabolism and Mood

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

SCANREP: Reliability of 3D Lower Limb Scanning

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Role of Adenosine in the Release of VEGF and Cytokines

rhBMP-2 in Cervical Arthrodesis

Intrapartum Epidural Catheter Displacement: Dressing Methods

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

KIDney Injury in Times of COVID-19 (KIDCOV)

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Letermovir for R+ Study

Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell): Delayed Impact

A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes

Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)

Effects of Pregabalin on Pain After Total Knee Arthroplasty

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma